The dysregulation of PDLIM1 usually manifests as its abnormal expression, which affects the interaction with its binding proteins and the related signal pathways (such as NF-κB, Wnt/β-catenin and Hippo), leading to the occurrence and development of many diseases including cancer. Here, PDLIM1 is linked to cancer.